182 related articles for article (PubMed ID: 8391830)
21. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
22. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
23. [Radionuclide imaging of neurendocrine tumors: biological basis and diagnostic results].
Genovese EA; Mallardo V; Rossi M; Vaccaro A; Raucci A; Della Vecchi N; Romano G; Califano T; Schillirò F
Recenti Prog Med; 2013; 104(7-8):340-4. PubMed ID: 24042404
[TBL] [Abstract][Full Text] [Related]
24. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
[TBL] [Abstract][Full Text] [Related]
25. [Somatostatin receptor scintigraphy in preoperative diagnosis of the site of endocrine gastrointestinal tumors].
Weinel RJ; Kisker O; Joseph K; Welcke U; Zaraca F; Rothmund M
Chirurg; 1994 Oct; 65(10):849-55. PubMed ID: 7821043
[TBL] [Abstract][Full Text] [Related]
26. [A new diagnostic method: somatostatin receptor scintigraphy of neuroendocrine tumors].
Westlin JE; Janson ET; Ahlström H; Ohrvall U; Arnberg H; Nilsson S; Akerström G; Oberg K
Lakartidningen; 1992 Dec; 89(50):4377-9. PubMed ID: 1469974
[No Abstract] [Full Text] [Related]
27. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors.
Kölby L; Wängberg B; Ahlman H; Tisell LE; Fjälling M; Forssell-Aronsson E; Nilsson O
World J Surg; 1998 Jul; 22(7):679-83. PubMed ID: 9606281
[TBL] [Abstract][Full Text] [Related]
28. Single-photon emission computed tomography tracers in the diagnostics of neuroendocrine tumors.
Pepe G; Bombardieri E; Lorenzoni A; Chiti A
PET Clin; 2014 Jan; 9(1):11-26. PubMed ID: 25029930
[TBL] [Abstract][Full Text] [Related]
29. Meta-[131I]iodobenzylguanidine in the scintigraphic evaluation of neural crest tumors.
Zagar I; Han R; Mitrovic S
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):13-6. PubMed ID: 9002742
[TBL] [Abstract][Full Text] [Related]
30. Use of radiolabeled somatostatin analogs in the identification and treatment of somatostatin receptor-bearing tumors.
Hurst RD; Modlin IM
Digestion; 1993; 54 Suppl 1():88-91. PubMed ID: 8359574
[TBL] [Abstract][Full Text] [Related]
31. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.
Reubi JC; Kvols LK; Waser B; Nagorney DM; Heitz PU; Charboneau JW; Reading CC; Moertel C
Cancer Res; 1990 Sep; 50(18):5969-77. PubMed ID: 2168286
[TBL] [Abstract][Full Text] [Related]
32. OctreoScan 111 for imaging of a somatostatin receptor-positive islet cell tumor in rat.
Bruns C; Stolz B; Albert R; Marbach P; Pless J
Horm Metab Res Suppl; 1993; 27():5-11. PubMed ID: 8392488
[TBL] [Abstract][Full Text] [Related]
33. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
[TBL] [Abstract][Full Text] [Related]
34. Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma.
Von Moll L; McEwan AJ; Shapiro B; Sisson JC; Gross MD; Lloyd R; Beals E; Beierwaltes WH; Thompson NW
J Nucl Med; 1987 Jun; 28(6):979-88. PubMed ID: 3035114
[TBL] [Abstract][Full Text] [Related]
35. Octreotide scintigraphy localizes somatostatin receptor-positive islet cell carcinomas.
Becker W; Marienhagen J; Scheubel R; Saptogino A; Bakker WH; Breeman WA; Wolf F
Eur J Nucl Med; 1991; 18(11):924-7. PubMed ID: 1684323
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs.
Dörr U; Wurm K; Höring E; Guzman G; Räth U; Bihl H
Horm Metab Res Suppl; 1993; 27():36-43. PubMed ID: 8330870
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome.
Krenning EP; Kwekkeboom DJ; Oei HY; de Jong RJ; Dop FJ; de Herder WW; Reubi JC; Lamberts SW
Digestion; 1994; 55 Suppl 3():54-9. PubMed ID: 7698538
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical identification of neuron-specific enolase, synaptophysin, chromogranin and endocrine granule constituent in neuroendocrine tumours.
Vyberg M; Horn T; Francis D; Askaa J
Acta Histochem Suppl; 1990; 38():179-81. PubMed ID: 1964227
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of somatostatin-receptor scintigraphy for detecting neuroendocrine tumors.
Meko JB; Doherty GM; Siegel BA; Norton JA
Surgery; 1996 Dec; 120(6):975-83; discussion 983-4. PubMed ID: 8957483
[TBL] [Abstract][Full Text] [Related]
40. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors.
Eriksson B; Bergström M; Lilja A; Ahlström H; Långström B; Oberg K
Acta Oncol; 1993; 32(2):189-96. PubMed ID: 7686763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]